News

Published Friday, June 29, 2018

The Neuroscience Pilot Award Program has granted eight research projects a total of $95,000 in pilot awards to enhance faculty research capability and productivity, with the long-term goal of stimulating growth of FAU extramural neuroscience funding. The 2018 award-winning projects are:

more»
Published Thursday, June 28, 2018

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells.

more»
Published Monday, June 18, 2018

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, discussed its improvements to productivity of its mAb yield using the C1 platform in an article published by BioProcess International and at the Global Bioprocessing and Bioanalytics Congress 2018.

more»
Published Thursday, June 7, 2018

This morning, the BDB hosted an active meeting of the Life Science Advisory Council, a group of dedicated stakeholders from across Palm Beach County’s vibrant Life Sciences Industry.

more»
Published Tuesday, June 5, 2018

In addition to receiving the top overall US ranking, Scripps Research was ranked first in its class in the United States in both life sciences and chemistry research.

more»
Published Monday, June 4, 2018

TD Solutions announced today that they have initiated development of Levellor™ HypoSpray Insulin for insulin-dependent diabetics. More than 6 million Americans use insulin in some form and that number will continue to rise.

more»
Published Wednesday, May 30, 2018

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative Palm Beach County based women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

more»
Published Friday, May 11, 2018

Officials at Boca Raton Regional Hospital today announced that it has pared its list of potential strategic partners to two finalists; Baptist Health South Florida and Cleveland Clinic.

more»

Investors